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The Government is Wrong: The Case for Human Gene Patents and the
Genomics Revolution
by Jonathan Stroud
Editor’s note: The following blog post was posted on www.ipbrief.net on
November 2nd, 2010.
The news media kicked up quite a fuss this spring
when a U.S. district court invalidated the patents on
two isolated genes that are strong indicators of a risk
of breast cancer. Association for Molecular Patenting
v. United States Patent and Trademark Association,
1:09-cv-04515-RWS (S.D.N.Y. Mar. 29, 2010); see
Blog Post of Kevin E. Noonan, Myriad Appeals AMP
v. USPTO Decision (June 16, 2010) (collecting news
articles and blog posts). The genes in question, BRCA1
and BRCA2, were researched, located, isolated, and
patented by Myriad Genetics, one of the older genetics
start-up companies (founded in 1991). They are among
over 2,000 existing gene patents, which grant market
exclusivity to inventors who have put in the work to
identify and isolate specific human genes. Friday, the
U.S. government unexpectedly reversed its previously
held position supporting such patents, and issued a
friend-of-the-court brief in the appeal of that case
condemning the patenting of isolated human genes.
Association for Molecular Patenting v. United States
Patent and Trademark Association, No. 2010-1406,
Amicus Curiae Brief for the United States in Support
of No One (Fed. Cir.) (filed Oct. 29, 2010).
The government is wrong. Because it will fuel
scientific progress, give a reasonable financial incentive
to companies interested in genomics, and lead to
further research in this rapidly expanding field, not to
mention the fact that it is consistent with prevailing
Federal Circuit precedent, the court should overturn
this dangerous ruling. The government should not
support the ruling, which in effect would invalidate
over 2,000 genomic patents. Instead, Congress should
selectively enact compulsory licenses on genetics
patents when the test and gene in question are so
significant that leaving the testing in the hands of one
company puts potentially life-saving testing out of the
reach of the average consumer. A sliding scale is more
appropriate than the current all-or-nothing approach.
First, background is important. Myriad is a
pioneer in a financially uncertain but potentially

revolutionary field. In his recent book Dr. Francis
Collins, the lead scientist in charge of the initial
mapping of the human genome and the current head
of the National Institute of Health, predicts that the
most significant change in health care will come from
advancements in genetic testing. Francis S. Collins,
The Language of Life (2010). Three companies already
offer personalized human genome mapping, and Dr.
Collins predicts this will soon become a mandatory
test required at birth and included in all individuals’
health records, as scientists isolate and characterize
more and more genes and their hereditary effects. Id.
at 44. (“Newborn screening [which already occurs for
very specific and treatable genetic conditions, such as
cystic fibrosis] seems almost certain to evolve into an
even broader and more comprehensive survey. . . . A
softer version of GATTACA may be coming soon.”)
Genes BRCA1 and 2 are well known in the
genomics field as some of the first genes whose
common genetic mutations show a significant increase
in the risk of a specific, treatable, and even sometimes
preventable condition, breast cancer. Id. at 27
(“women who carry a BRCA1 mutation have about
an 80 percent lifetime risk of developing breast cancer
and a 50 percent risk of developing ovarian cancer.”).
Myriad was the first to identify a method of testing
for the genes and has moved to protect its interest as
the sole holder of a suite of patents for those isolation
and testing methods. Myriad, attempting to remain
profitable while conducting further research and
recouping the investment it has already put in through
its initial research, is charging roughly $3,000 for the
test. AMP v. USPTO 1:09-cv-04515-RWS. at 52-78.
The ACLU, breast cancer interest groups, and now
the U.S. government oppose these patents as profiting
from what is essentially our own human body, which
they argue violates the statutory grant to the USPTO
under 35 U.S.C. § 101, violates our individual First
Amendment rights, and prevents lifesaving testing
from being widely used. Their opposition is too
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extreme, misunderstands the important place of
industry in genetic research, and makes it harder for
technology and research in genomics to grow at the
current rapid pace. Furthermore, it is consistent with
all of the known precedent concerning gene isolation
patents, as well as with the over 2,000 patents the
USPTO has granted consistent with their policies.
To be sure, no one wants important and potentially
life-saving tests for breast cancer to be out of reach of
the American public. That is why a congressionally
mandated compulsory license is more appropriate for
genetic tests of strong indicators of treatable serious
conditions, particularly in the case of public hospitals
and research institutions. Such a license would allow
other companies and researchers to use the tests for a
set licensing fee, and in certain limited cases, for free,
which would reward and compensate Myriad for their
research while striking the balance with public access
to the tests.
However, simply invalidating the patents would
give Myriad and other genetic start-up companies
absolutely no incentive to research in this volatile
and uncertain field, and will actually stifle genomic
innovation in the end at a key time in the industry’s
adolescence. In a perfect world, well-funded
government researchers in highly regarded public
universities and research centers would exclusively
carry out this important work, they would excel in
the endeavor, and that would be sufficient. But absent
some windfall grant of funding to the NIH or some
newly instituted and very well-funded prize program,
Congress needs to act to limit the reach of such
intellectual property while ignoring a more sweeping
and dangerous open grant, which offers no incentives
whatsoever for companies to invest in key lifesaving
research. To invalidate these patents would be far more
dangerous to our health in the long run, and would put
our industry and nation at a disadvantage worldwide
in one of the only scientific fields in which we are still a
leader, the genomics revolution.
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